It efficiently antagonizes RIF-induced PXR activation, and inhibits the activity of CYP3A enzyme as well as MDR-1, MRP2 expression in ovarian cancer, liver cancer, and colon cancer cells. Here, CYP3A4 is linked to ovarian cancer.